NCT06849167View on ClinicalTrials.gov

Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2029

Study Completion Date

March 1, 2030

Conditions
Non-Small Cell Lung Cancer
Interventions
RADIATION

hypofractionated radiotherapy with immunotherapy

Immunotherapy combined with hypofractionated concurrent chemoradiotherapy followed by consolidation immunotherapy

Trial Locations (1)

Unknown

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER